Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.
Date
2022-07-01Author
Gillessen, S
Armstrong, A
Attard, G
Beer, TM
Beltran, H
Bjartell, A
Bossi, A
Briganti, A
Bristow, RG
Bulbul, M
Caffo, O
Chi, KN
Clarke, CS
Clarke, N
Davis, ID
de Bono, JS
Duran, I
Eeles, R
Efstathiou, E
Efstathiou, J
Ekeke, ON
Evans, CP
Fanti, S
Feng, FY
Fizazi, K
Frydenberg, M
George, D
Gleave, M
Halabi, S
Heinrich, D
Higano, C
Hofman, MS
Hussain, M
James, N
Jones, R
Kanesvaran, R
Khauli, RB
Klotz, L
Leibowitz, R
Logothetis, C
Maluf, F
Millman, R
Morgans, AK
Morris, MJ
Mottet, N
Mrabti, H
Murphy, DG
Murthy, V
Oh, WK
Ost, P
O'Sullivan, JM
Padhani, AR
Parker, C
Poon, DMC
Pritchard, CC
Rabah, DM
Rathkopf, D
Reiter, RE
Rubin, M
Ryan, CJ
Saad, F
Sade, JP
Sartor, O
Scher, HI
Shore, N
Skoneczna, I
Small, E
Smith, M
Soule, H
Spratt, DE
Sternberg, CN
Suzuki, H
Sweeney, C
Sydes, MR
Taplin, M-E
Tilki, D
Tombal, B
Türkeri, L
Uemura, H
Uemura, H
van Oort, I
Yamoah, K
Ye, D
Zapatero, A
Omlin, A
Type
Journal Article
Metadata
Show full item recordAbstract
BACKGROUND: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. The 2021 Advanced Prostate Cancer Consensus Conference (APCCC) addressed some of these questions to supplement guidelines that are based on level 1 evidence. OBJECTIVE: To present the voting results from APCCC 2021. DESIGN, SETTING, AND PARTICIPANTS: The experts identified three major areas of controversy related to management of advanced prostate cancer: newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), the use of prostate-specific membrane antigen ligands in diagnostics and therapy, and molecular characterisation of tissue and blood. A panel of 86 international prostate cancer experts developed the programme and the consensus questions. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The panel voted publicly but anonymously on 107 pre-defined questions, which were developed by both voting and non-voting panel members prior to the conference following a modified Delphi process. RESULTS AND LIMITATIONS: The voting reflected the opinions of panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results reported in the Supplementary material. CONCLUSIONS: These voting results from a panel of experts in advanced prostate cancer can help clinicians and patients to navigate controversial areas of management for which high-level evidence is scant. However, diagnostic and treatment decisions should always be individualised according to patient characteristics, such as the extent and location of disease, prior treatment(s), comorbidities, patient preferences, and treatment recommendations, and should also incorporate current and emerging clinical evidence and logistic and economic constraints. Enrolment in clinical trials should be strongly encouraged. Importantly, APCCC 2021 once again identified salient questions that merit evaluation in specifically designed trials. PATIENT SUMMARY: The Advanced Prostate Cancer Consensus Conference is a forum for discussing current diagnosis and treatment options for patients with advanced prostate cancer. An expert panel votes on predefined questions focused on the most clinically relevant areas for treatment of advanced prostate cancer for which there are gaps in knowledge. The voting results provide a practical guide to help clinicians in discussing treatment options with patients as part of shared decision-making.
Collections
Subject
(177)Lu-PSMA therapy
Advanced prostate cancer
Castration-resistant prostate cancer
Genetics
Hormone-sensitive prostate cancer
Imaging
Next-generation sequencing
PARP inhibition
Prostate cancer treatment
Tumour genomic profiling
Consensus
Humans
Male
Prostatic Neoplasms
Research team
PrCa Targeted Therapy
Oncogenetics
Language
eng
Date accepted
2022-04-01
License start date
2022-07-01
Citation
European Urology, 2022, 82 (1), pp. 115 - 141
Publisher
ELSEVIER
Except where otherwise noted, this item's license is described
as
https://creativecommons.org/licenses/by-nc-nd/4.0/
Related items
Showing items related by title, author, creator and subject.
-
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
Gillessen, S; Bossi, A; Davis, ID; de Bono, J; Fizazi, K; et al. (ELSEVIER SCI LTD, 2023-05-01)BACKGROUND: Innovations in imaging and molecular characterisation together with novel treatment options have improved outcomes in advanced prostate cancer. However, we still lack high-level evidence in many areas relevant ... -
Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study
Berney, DM; Gopalan, A; Kudahetti, S; Fisher, G; Ambroisine, L; et al. (NATURE PUBLISHING GROUP, 2009-03-17)Treatment decisions after diagnosis of clinically localised prostate cancer are difficult due to variability in tumour behaviour. We therefore examined one of the most promising biomarkers in prostate cancer, Ki-67, in a ... -
Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL).
Dearnaley, D; Griffin, CL; Lewis, R; Mayles, P; Mayles, H; et al. (ELSEVIER SCIENCE INC, 2019-03-01)PURPOSE: To establish the toxicity profile of high-dose pelvic lymph node intensity-modulated radiation therapy (IMRT) and to assess whether it is safely deliverable at multiple centers. METHODS AND MATERIALS: In this phase ...